Cargando…
Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
BACKGROUND: Scarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Ch...
Autores principales: | Xiang, Yirong, Li, Mengtao, Luo, Hui, Wang, Yanhong, Duan, Xinwang, Zhao, Cheng, Zhan, Feng, Wu, Zhenbiao, Li, Hongbin, Yang, Min, Xu, Jian, Wei, Wei, Wu, Lijun, You, Hanxiao, Qian, Junyan, Yang, Xiaoxi, Huang, Can, Zhao, Jiuliang, Wang, Qian, Leng, Xiaomei, Tian, Xinping, Zhao, Yan, Zeng, Xiaofeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802218/ https://www.ncbi.nlm.nih.gov/pubmed/33430947 http://dx.doi.org/10.1186/s13075-020-02407-5 |
Ejemplares similares
-
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
por: Gui, Yinli, et al.
Publicado: (2022) -
Chinese SLE Treatment and Research Group (CSTAR) Registry 2009–2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus
por: Li, Mengtao, et al.
Publicado: (2021) -
Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus
por: Shi, Yue, et al.
Publicado: (2022) -
Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
por: Cheng, Cheng, et al.
Publicado: (2023) -
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
por: Jiang, Nan, et al.
Publicado: (2022)